Quick Facts About DVT/PE in Oncology

DVT/PE Incidence and Impact

  • Deep vein thrombosis and pulmonary embolism (DVT/PE) are often underdiagnosed and serious, but preventable medical conditions.
  • It is estimated that up to 600,000 people in the United States are affected by DVT/PE each year, and that up to 100,000 Americans die each year due to DVT/PE.
  • 10% to 30% of people affected by DVT/PE will die within one month of diagnosis.
  • In about 25% of people who experience a PE, the first “symptom” is sudden death.
  • Among people who have had a DVT, one-third will have long-term complications (post-thrombotic syndrome) such as swelling, pain, discoloration, and scaling in the affected limb.
  • One-third (about 33%) of people with DVT/PE will have a recurrence within 10 years.

DVT/PE in Oncology

  •  All patients with active cancer are at increased risk for DVT/PE, but the risk is greater for cancer patients who are hospitalized, have surgery, or undergo certain types of cancer treatment, such as chemotherapy or radiation.
  • Without prophylaxis (preventative anticoagulant medication), 40% to 80% of surgical oncology patients will develop DVT in the calf vein.
  • Without prophylaxis, 4% to 10% of surgical oncology patients will develop PE, and about 1% to 5% of these PEs will be fatal.
  • Mortality is greater among cancer patients with DVT/PE than among those with cancer alone.

NBCA DVT/PE Awareness Survey Results – Oncology – Read More
DVT/PE Prophylaxis Underutilized – Read More
Risk Versus Awareness and Information – Read More
NBCA Survey Methodology – Read More

<<<Previous  1 | 2 | 3 | 4 | 5  Next >>>

The NBCA DVT/PE Awareness Survey was made possible by a grant from Ortho-McNeil™, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Current News

The National Blood Clot Alliance Launches New Council for Emerging Researchers in Thrombosis (CERT)

FOR IMMEDIATE RELEASE: 07/28/2022   The National Blood Clot Alliance (NBCA), the nation’s leading nonprofit patient advocacy organization dedicated to…

The FUVID Study

The FUVID Study (Functional Characterization of Chronic Thromboembolic Venous Disease in Children) is currently open for enrollment to qualified participants.…